Close
Achema

OpenCell Technologies Appoints CEO

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

OpenCell Technologies, an R&D-stage biomedical venture, has appointed Kevin Gutshall as chief executive officer to lead efforts to translate and commercialize its core technology platform, POROS. Kevin joins the company from MilliporeSigma where he served as director of life science business development and M&A focusing on the cell and gene therapy business unit.

OpenCell was established based on technology developed at the Georgia Institute of Technology, which has broad applications ranging from fuel and energy to life sciences, is focused on the rapidly emerging cell and gene therapy market.

During its seed stage, the company benefitted from BioGenerator Entrepreneurs-in-Residence (EIR) that brought key expertise to the company as it pivoted from the research tools market to cell and gene therapy applications. Paul Olivo, MD, PhD, a former BioGenerator EIR and current Venture Partner at Synchrony Bio, which also participated in the current financing, serves as a key advisor to OpenCell, managing the company’s research team. In her role as BioGenerator EIR, Heather Holeman, PhD, now CEO of Lifespan Biosciences, facilitated key business development connections for the company. Concurrent with the financing, Charlie Bolten, Senior Vice President of BioGenerator, joins OpenCell’s board of directors.

Latest stories

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back